- Home
- BIIB vs KEY Comparison
BIIB vs KEY Comparison
Compare BIIB & KEY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- KEY
- Stock Information
- Founded
- BIIB 1978
- KEY 1825
- Country
- BIIB United States
- KEY United States
- Employees
- BIIB N/A
- KEY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- KEY Major Banks
- Sector
- BIIB Health Care
- KEY Finance
- Exchange
- BIIB Nasdaq
- KEY Nasdaq
- Market Cap
- BIIB 24.2B
- KEY 20.8B
- IPO Year
- BIIB 1991
- KEY N/A
- Fundamental
- Price
- BIIB $175.74
- KEY $17.84
- Analyst Decision
- BIIB Buy
- KEY Buy
- Analyst Count
- BIIB 23
- KEY 16
- Target Price
- BIIB $176.48
- KEY $20.41
- AVG Volume (30 Days)
- BIIB 2.0M
- KEY 18.7M
- Earning Date
- BIIB 10-30-2025
- KEY 10-16-2025
- Dividend Yield
- BIIB N/A
- KEY 4.75%
- EPS Growth
- BIIB N/A
- KEY 34785.88
- EPS
- BIIB 10.97
- KEY 0.86
- Revenue
- BIIB $10,065,900,000.00
- KEY $5,934,000,000.00
- Revenue This Year
- BIIB $2.97
- KEY $77.14
- Revenue Next Year
- BIIB N/A
- KEY $6.45
- P/E Ratio
- BIIB $15.97
- KEY $20.61
- Revenue Growth
- BIIB 4.77
- KEY 22.30
- 52 Week Low
- BIIB $110.04
- KEY $12.73
- 52 Week High
- BIIB $176.02
- KEY $20.04
- Technical
- Relative Strength Index (RSI)
- BIIB 76.31
- KEY 52.84
- Support Level
- BIIB $165.75
- KEY $16.91
- Resistance Level
- BIIB $170.78
- KEY $18.47
- Average True Range (ATR)
- BIIB 5.16
- KEY 0.45
- MACD
- BIIB 1.34
- KEY 0.01
- Stochastic Oscillator
- BIIB 98.74
- KEY 58.65
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.